The Fort Worth Press - Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses

USD -
AED 3.672503
AFN 63.999817
ALL 82.450149
AMD 357.809202
ANG 1.790403
AOA 917.499877
ARS 1549.874098
AUD 1.484483
AWG 1.8025
AZN 1.701804
BAM 1.7757
BBD 2.012982
BDT 124.44505
BGN 1.77347
BHD 0.377199
BIF 3005
BMD 1
BND 1.288366
BOB 11.659547
BRL 5.782163
BSD 0.99941
BTN 93.823002
BWP 13.990966
BYN 3.003223
BYR 19600
BZD 2.010077
CAD 1.429775
CDF 2318.000248
CHF 0.839835
CLF 0.025358
CLP 998.039782
CNY 6.66455
CNH 6.664155
COP 3318.97
CRC 445.37243
CUC 1
CUP 23.986201
CVE 100.374973
CZK 22.19355
DJF 177.719967
DKK 6.79487
DOP 60.550244
DZD 137.065944
EGP 53.6853
ERN 15
ETB 161.249886
EUR 0.90898
FJD 2.28475
FKP 0.756558
GBP 0.758315
GEL 2.594973
GGP 0.756558
GHS 11.734977
GIP 0.756558
GMD 73.500352
GNF 8859.999657
GTQ 7.63916
GYD 209.138162
HKD 7.84625
HNL 27.06947
HRK 6.831965
HTG 130.99394
HUF 330.970967
IDR 18279
ILS 3.24365
IMP 0.756558
INR 93.93975
IQD 1515
IRR 1925254.000425
ISK 124.339896
JEP 0.756558
JMD 158.482001
JOD 0.709041
JPY 159.416016
KES 130.039708
KGS 87.449402
KHR 4080.000054
KMF 447.50406
KPW 900.00035
KRW 1336.365011
KWD 0.31162
KYD 0.833012
KZT 444.73296
LAK 22524.999912
LBP 89550.0002
LKR 332.650884
LRD 168.501261
LSL 16.984982
LTL 2.95274
LVL 0.60489
LYD 6.455006
MAD 9.99725
MDL 18.281771
MGA 4594.000024
MKD 55.947457
MMK 2099.568705
MNT 3604.028735
MOP 8.07799
MRU 40.649826
MUR 47.819509
MVR 15.410198
MWK 1737.000365
MXN 18.52304
MYR 4.094017
MZN 63.910219
NAD 16.984964
NGN 1345.879753
NIO 36.750192
NOK 9.655665
NPR 150.11644
NZD 1.81763
OMR 0.384501
PAB 0.999532
PEN 3.408199
PGK 4.513966
PHP 63.918496
PKR 276.374515
PLN 4.001145
PYG 6202.732761
QAR 3.644022
RON 4.857802
RSD 106.930999
RUB 82.598883
RWF 1477
SAR 3.763042
SBD 8.098361
SCR 13.860567
SDG 601.548038
SEK 10.094865
SGD 1.288925
SHP 0.758581
SLE 23.04986
SLL 20969.503664
SOS 572.511276
SRD 37.453496
STD 20697.981008
STN 22.375
SVC 8.745744
SYP 13002.000337
SZL 16.984982
THB 33.885502
TJS 9.210795
TMT 3.51
TND 3.041994
TOP 2.40776
TRY 50.421202
TTD 6.787708
TWD 32.977904
TZS 2644.992965
UAH 45.435091
UGX 4147.791748
UYU 40.582868
UZS 12024.999857
VES 914.603597
VND 25764
VUV 120.719595
WST 2.810584
XAF 596.252115
XAG 0.021223
XAU 0.000259089508
XCD 2.70255
XCG 1.801394
XDR 0.707052
XOF 596.252115
XPF 108.875027
YER 236.501049
ZAR 16.96925
ZMK 9001.199115
ZMW 20.4664
ZWL 321.999592
SSP 5945.381189
MXV 2.078532
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses
Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses

Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses

Oxidative stress drives aging and is a key factor in diseases like Alzheimer's, Age-related Macular Degeneration (AMD), cardiovascular diseases, cancer, and diabetes. It also plays a critical role in the progression of viral infections, such as avian influenza (bird flu), by exacerbating inflammation and cellular damage. Directly addressing oxidative stress and its consequences is essential to treating the underlying causes of these conditions and mitigating the severity of viral outbreaks.

Text size:

MIAMI, FLORIDA / ACCESS Newswire / January 28, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or Telomir, a leader in age-reversal science, today announced groundbreaking results from its recent preclinical studies conducted in human cell lines. These studies demonstrated the ability of Telomir-1 to fully reverse copper-induced elevation of Reactive Oxygen Species (ROS) and provide robust cellular protection against copper toxicity.

"The results of our studies demonstrate the exceptional potential of Telomir-1 in addressing oxidative stress and its related pathologies," said Raphael Mayer, Ph.D., Founder and CEO of Smart Assays Biotechnologies Ltd. "Telomir-1's ability to fully normalize copper-induced ROS and to protect the cells from damage represents a significant leap forward in our understanding of this compound's therapeutic potential."

Oxidative stress occurs when there is an imbalance between free radicals and antioxidants in the body. This imbalance leads to the generation of harmful ROS, which can damage cellular structures, including DNA, mitochondria, proteins, and lipids. It plays a central role in the progression of diseases such as Alzheimer's, AMD, cancer, cardiovascular conditions, and diabetes. Furthermore, oxidative stress accelerates telomere shortening, compromising cellular repair mechanisms and contributing to aging and disease development.

In the context of viral infections, such as avian influenza (bird flu), oxidative stress is a key factor in disease severity. Viral infections trigger and exploit excessive ROS production as a mode to facilitate their replication, leading to widespread inflammation, cellular damage, and impaired immune responses. This oxidative damage exacerbates disease progression and increases the risk of severe outcomes. Addressing oxidative stress in viral infections is critical for mitigating these effects and improving patient recovery.

Telomir-1's potential ability to shield cells from copper toxicity is particularly significant in diseases linked to copper dysregulation. Conditions such as Wilson's disease, AMD, and Alzheimer's disease are directly affected by excess copper, which exacerbates oxidative stress and cellular damage. By mitigating copper toxicity, Telomir-1 offers a targeted approach to protecting cellular health and addressing the root causes of these debilitating diseases.

Erez Aminov, Chairman and CEO of Telomir, added, "With its unique regulatory mechanism and broad application, Telomir-1 is more than a single treatment-it is a platform that could potentially transform healthcare for millions. In addition to addressing age-related diseases, we are exploring its role in combating oxidative stress in viral infections such as avian influenza (bird flu). The urgent need for effective treatments underscores the importance of Telomir-1 in reducing the severe effects of oxidative stress during outbreaks. Our mission is to leverage its capabilities to address unmet medical needs and improve patient outcomes worldwide.

Key findings from the study include:

  • Reversal of Oxidative Stress: Telomir-1 has potential to fully normalize ROS levels, effectively reversing oxidative damage in human cell lines.

  • Cellular Protection: Telomir-1 provided strong protection against copper-induced toxicity while maintaining cellular integrity.

  • Regulatory Mechanism: Telomir-1 demonstrated effects at doses significantly lower than copper levels, indicating its unique regulatory mechanism beyond copper ion chelation.

Dr. Itzchak Angel, Chief Scientific Advisor at Telomir, commented, "These findings underscore the unique profile of Telomir-1 as an intracellular regulator of oxidative stress. Its ability to act at low doses, rather than as a chelator, to reverse copper-induced ROS and toxicity positions it as a promising candidate for multiple indications, including neurodegeneration and metabolic disorders."

Transformative Potential for Wilson's Disease, Alzheimer's, AMD, Cancer, and Cardiovascular Diseases

  • Wilson's Disease: A rare genetic disorder caused by excessive copper accumulation, affecting approximately 1 in 30,000 people globally. Current treatments come with severe side effects, but Telomir-1's ability to regulate copper metabolism and normalize ROS presents a promising alternative to address the root causes of the disease while minimizing adverse effects.

  • Alzheimer's Disease: Oxidative stress, particularly the one associated with copper, contributes to neurodegeneration, protein misfolding and aggregation, and subsequent cognitive decline. By reversing the oxidative damage, Telomir-1 offers the potential to slow or halt disease progression and improve patient outcomes.

  • Age-related Macular Degeneration (AMD): Oxidative stress is a major driver of retinal damage and vision loss in AMD. Telomir-1's protective effects on cells could provide a novel approach to preserving vision and addressing the underlying causes of this condition.

  • Cancer: Oxidative stress fuels DNA damage, tumor growth, and resistance to treatments like chemotherapy. Telomir-1's ability to reverse ROS damage positions it as a potential adjunct to improve cancer therapies and patient survival rates.

  • Cardiovascular Diseases: Oxidative stress impairs vascular function, accelerates atherosclerosis, ischemic conditions, and exacerbates chronic inflammation. Telomir-1's regulatory effects could protect cardiovascular health and reduce the risk of these conditions.

Telomir-1's ability to reverse oxidative damage and protect cells highlights its transformative potential across these diseases, offering innovative solutions to improve patient care.

Future Exploration: Oxidative Stress and Viruses, Including Avian Influenza (Bird Flu)

Telomir is also exploring the application of Telomir-1 as an oral treatment for oxidative stress caused by viral infections, including emerging threats such as avian influenza (bird flu). The bird flu has infected over 868 people globally as of 2023, with a mortality rate of approximately 50%, according to the World Health Organization (WHO). Recent adaptations of the virus for human transmission have raised significant public health concerns. The U.S. government has allocated significant funding, exceeding $1 billion, to accelerate the development of effective therapies for viral outbreaks like bird flu.

This zoonotic virus is characterized by severe inflammation and elevated oxidative stress, both of which contribute to rapid disease progression and organ damage. Currently, there are no approved drugs specifically targeting the oxidative stress caused by the bird flu or similar viruses. Telomir-1's ability to reverse oxidative stress and protect cells offers a promising avenue for addressing this gap. By mitigating the cellular damage associated with oxidative stress, Telomir-1 has the potential to play a critical role in reducing the severity of such infections. This represents a key area of future investigation for Telomir.

About Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) is a pre-clinical stage pharmaceutical company seeking to lead development in several areas, including age-reversal science. Telomir is focused on the development of Telomir-1, a novel small molecule metal ion regulator designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process. Telomir's goal is to explore the potential of Telomir-1 starting with ongoing research in animals and then in humans.

Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and age-related diseases. Telomir's goal is to develop and gain regulatory approval for Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life.

Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing.

Cautionary Note Regarding Forward-Looking Statements

This press release, statements of Telomir Pharmaceuticals' management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements.

These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.

Contact Information

Helga Moya
[email protected]
(786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc



View the original press release on ACCESS Newswire

S.Rocha--TFWP